LFVN

LIFEVANTAGE CORP

Consumer Defensive | Micro Cap

$0.14

EPS Forecast

$46.64

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-09-18

LifeVantage 2026: A Modest Recalibration as Revenue Dips and EPS Flexes Under Pressure

LifeVantage Corporation (Nasdaq: LFVN) reports Q4 2026 results and full-year performance; analysis below reads like a balance-scale of cells and percentages.

LifeVantage, the Salt Lake City–based wellness company, disclosed its fourth quarter of fiscal 2026 and full-year results on August 27, 2026. The press release lays out a clear pattern: revenue is down year over year, margins are modestly managed, and diluted earnings per share (EPS) sit in a range that suggests ongoing profitability albeit with pressure from the top line. For readers tracking earnings metrics, the report includes GAAP EPS (net income per diluted share), adjusted EPS, and adjusted EBITDA, alongside geographic performance. As with most enterprise disclosures, the document carries the usual mix of formal boilerplate and a few numbers you’d rather see trending up. Importantly, there’s no explicit forward-looking revenue forecast in the excerpt, and the release does not present a disclosed EPS consensus figure from sell-side analysts.

Q4 2026 Highlights

The company reported revenue of $42.4 million for the fourth quarter, a decline of 23.1% versus the prior year period. Regional performance was hard on the wallet: revenue in the Americas fell 24.8%, while Asia/Pacific & Europe declined by 16.9%. On the profitability side, net income per diluted share came in at $0.10, compared with $0.15 a year earlier. Adjusted earnings per diluted share stood at $0.11, down from $0.17 in the prior-year quarter. Adjusted EBITDA was $2.7 million, versus $4.8 million in the fourth quarter of the prior year.

Fiscal Year 2026: A Year in Review

For the full year, LifeVantage reported revenue of $182.6 million, down 20.1% from the previous year. The geographic mix showed a similar pattern: Americas revenue down 23.2%, and Asia/Pacific & Europe down 6.9%. Net income per diluted share was $0.40, down from $0.75 a year ago. Adjusted earnings per diluted share came in at $0.56, versus $0.82 in the prior year. The release also notes an Adjusted EBITDA line for the annual period, though the exact figure isn’t reiterated in the excerpt beyond the quarterly comparison noted above.

Regional Pain Points and Earnings Metrics

  • Revenue: Q4 $42.4M; FY2026 $182.6M
  • Americas: Q4 down ~25%; FY down ~23%
  • Asia/Pacific & Europe: Q4 down ~17%; FY down ~7%
  • EPS: Q4 GAAP $0.10; Q4 adjusted $0.11; FY GAAP $0.40; FY adjusted $0.56
  • Adjusted EBITDA: Q4 $2.7M (vs. $4.8M prior year); FY figure not restated in the excerpt
  • Notes: The release emphasizes year-over-year comparisons; no explicit EPS consensus or revenue forecast is provided in the excerpt

What It Might Portend for LifeVantage and Peers

There’s a recurring theme in disclosures like this: when a company’s top line contracts across geographies, the margin story becomes the critical lever. LifeVantage’s Q4 numbers show that even with disciplined expense management, the revenue declines translated into weaker per-share results, both GAAP and adjusted. The drop in Adjusted EBITDA for the quarter underscores the cost of maintaining scale in a slowing revenue environment.

From a market structure perspective, a few implications emerge. First, the Americas remain a pressure point—almost 25% weaker in Q4 and over 23% for the year—raising questions about channel dynamics, product lifecycle, and any macro headwinds in consumer wellness spend. Second, the softness in Asia/Pacific & Europe—though not as severe as the Americas—still signals that growth vectors in international markets need attention, whether through localization, product adaptation, or partner networks.

Absent a stated revenue forecast, investors are left to infer the tone of guidance from the cadence of results and the level of detail around initiatives. A lack of explicit EPS consensus or forward-looking revenue targets means the company is not signaling a clear path to a near-term acceleration, which could influence how the stock trades relative to peers that do offer more explicit guidance. In this context, EPS and adjusted EPS trends become the nearest, albeit imperfect, proxy for investor expectations.

Implications for Sector Peers

For LifeVantage’s peers in the consumer wellness and direct-to-consumer space, the quarter reinforces a familiar motif: growth becomes precarious as revenue slows, and the margin cushion tests discipline and cost structure. Peers with stronger geographic diversification or higher-margin product lines may weather the downturn better, while those with heavier dependence on a single region could see more pronounced effects. The absence of a clear revenue forecast from LifeVantage may widen gaps in relative valuation among sector players, particularly for companies whose stock prices react to forward-looking projections as much as to current results.

Notes on the Disclosure

The press release frames the numbers with standard caution about year-over-year comparisons and notes that All comparisons are on a year-over-year basis for the Fourth Quarter of Fiscal 2026 vs. the Fourth Quarter of Fiscal 2025. The location and date—Salt Lake City, Utah on August 27, 2026—anchor the disclosure as a typical corporate earnings release. The document presents both GAAP and non-GAAP metrics (Adjusted EPS and Adjusted EBITDA), a common approach to illustrate performance independent of certain non-cash or non-recurring items.

Bottom Line

LifeVantage’ s fiscal 2026 results tell a story of a company navigating a tougher revenue environment while maintaining discipline around profitability metrics. The headline numbers suggest a contraction in scale, with EPS and adjusted EBITDA reflecting the downside of a slower top line. For investors, the question remains whether the company can reverse the revenue decline—without sacrificing the quality of earnings—and whether management can articulate a credible path back to growth in the next year’s revenue forecast and beyond. The sector will be watching closely to see if LifeVantage’s strategic moves in international markets and any product or go-to-market adjustments begin to show up as a stabilizing force in 2027.

Quick Reference Data (for the curious)

  • Stock ticker: LFVN
  • Q4 revenue: $42.4 million; YoY change: -23.1%
  • Q4 diluted EPS (GAAP): $0.10; Q4 adjusted EPS: $0.11
  • Q4 Adjusted EBITDA: $2.7 million (vs $4.8 million prior year)
  • FY2026 revenue: $182.6 million; YoY change: -20.1%
  • FY diluted EPS (GAAP): $0.40; FY adjusted EPS: $0.56
  • Geographic note: Americas softness; Asia/Pacific & Europe also lower
  • Forward-looking indicators: no revenue forecast provided in the excerpt; no explicit EPS consensus disclosed